http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 23 Jun 2025 16:06:16 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/iMDx+%28IMDX%29+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965076.html <p>Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a head-to-head comparison with another commercially available test kit.</p><p> </p><p>The findings indicated equivalent measurements of donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker used to assess the risk of transplant rejection, between the two platforms studied.</p><p>This positive data supports iMDx’s top priority of launching its first clinical molecular diagnostic test kit and capturing value in the estimated $1 billion transplant rejection testing market. In 2025 to date, iMDx is executing the key steps typically necessary to transition from product development http://www.streetinsider.com/Corporate+News/iMDx+%28IMDX%29+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965076.html Mon, 23 Jun 2025 16:06:16 -0400 IMDX OCX http://www.streetinsider.com/Corporate+News/iMDx+%28IMDX%29+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965076.html <p>Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a head-to-head comparison with another commercially available test kit.</p><p> </p><p>The findings indicated equivalent measurements of donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker used to assess the risk of transplant rejection, between the two platforms studied.</p><p>This positive data supports iMDx’s top priority of launching its first clinical molecular diagnostic test kit and capturing value in the estimated $1 billion transplant rejection testing market. In 2025 to date, iMDx is executing the key steps typically necessary to transition from product development http://www.streetinsider.com/Corporate+News/iMDx+%28IMDX%29+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965076.html Mon, 23 Jun 2025 16:06:16 -0400 IMDX OCX http://www.streetinsider.com/FDA/iMDx+%28IMDX%29+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965076.html <p>Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a head-to-head comparison with another commercially available test kit.</p><p> </p><p>The findings indicated equivalent measurements of donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker used to assess the risk of transplant rejection, between the two platforms studied.</p><p>This positive data supports iMDx’s top priority of launching its first clinical molecular diagnostic test kit and capturing value in the estimated $1 billion transplant rejection testing market. In 2025 to date, iMDx is executing the key steps typically necessary to transition from product development http://www.streetinsider.com/FDA/iMDx+%28IMDX%29+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965076.html Mon, 23 Jun 2025 16:06:16 -0400 IMDX OCX http://www.streetinsider.com/FDA/iMDx+%28IMDX%29+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965076.html <p>Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a head-to-head comparison with another commercially available test kit.</p><p> </p><p>The findings indicated equivalent measurements of donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker used to assess the risk of transplant rejection, between the two platforms studied.</p><p>This positive data supports iMDx’s top priority of launching its first clinical molecular diagnostic test kit and capturing value in the estimated $1 billion transplant rejection testing market. In 2025 to date, iMDx is executing the key steps typically necessary to transition from product development http://www.streetinsider.com/FDA/iMDx+%28IMDX%29+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965076.html Mon, 23 Jun 2025 16:06:16 -0400 IMDX OCX http://www.streetinsider.com/Press+Releases/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html <ul><li><strong>Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits</strong></li><li><strong>Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients</strong></li><li><strong>Data was presented at the European Renal Association (ERA) 2025</strong></li><li><strong>Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2</strong></li><li><strong>Upcoming National Principal Investigator and Key Opinion Leader call planned</strong><br/></li></ul> <p>NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a http://www.streetinsider.com/Press+Releases/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html Mon, 23 Jun 2025 16:05:00 -0400 A.19718279 IMDX O.01951358 O.07511324 OCX http://www.streetinsider.com/Press+Releases/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html <ul><li><strong>Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits</strong></li><li><strong>Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients</strong></li><li><strong>Data was presented at the European Renal Association (ERA) 2025</strong></li><li><strong>Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2</strong></li><li><strong>Upcoming National Principal Investigator and Key Opinion Leader call planned</strong><br/></li></ul> <p>NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a http://www.streetinsider.com/Press+Releases/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html Mon, 23 Jun 2025 16:05:00 -0400 A.19718279 IMDX O.01951358 O.07511324 OCX http://www.streetinsider.com/Press+Releases/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html <ul><li><strong>Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits</strong></li><li><strong>Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients</strong></li><li><strong>Data was presented at the European Renal Association (ERA) 2025</strong></li><li><strong>Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2</strong></li><li><strong>Upcoming National Principal Investigator and Key Opinion Leader call planned</strong><br/></li></ul> <p>NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a http://www.streetinsider.com/Press+Releases/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html Mon, 23 Jun 2025 16:05:00 -0400 A.19718279 IMDX O.01951358 O.07511324 OCX http://www.streetinsider.com/Press+Releases/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html <ul><li><strong>Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits</strong></li><li><strong>Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients</strong></li><li><strong>Data was presented at the European Renal Association (ERA) 2025</strong></li><li><strong>Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2</strong></li><li><strong>Upcoming National Principal Investigator and Key Opinion Leader call planned</strong><br/></li></ul> <p>NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a http://www.streetinsider.com/Press+Releases/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html Mon, 23 Jun 2025 16:05:00 -0400 A.19718279 IMDX O.01951358 O.07511324 OCX http://www.streetinsider.com/Press+Releases/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html <ul><li><strong>Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits</strong></li><li><strong>Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients</strong></li><li><strong>Data was presented at the European Renal Association (ERA) 2025</strong></li><li><strong>Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2</strong></li><li><strong>Upcoming National Principal Investigator and Key Opinion Leader call planned</strong><br/></li></ul> <p>NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a http://www.streetinsider.com/Press+Releases/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html Mon, 23 Jun 2025 16:05:00 -0400 A.19718279 IMDX O.01951358 O.07511324 OCX http://www.streetinsider.com/Globe+Newswire/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html <ul><li><strong>Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits</strong></li><li><strong>Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients</strong></li><li><strong>Data was presented at the European Renal Association (ERA) 2025</strong></li><li><strong>Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2</strong></li><li><strong>Upcoming National Principal Investigator and Key Opinion Leader call planned</strong><br/></li></ul> <p>NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a http://www.streetinsider.com/Globe+Newswire/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html Mon, 23 Jun 2025 16:05:00 -0400 A.19718279 IMDX O.01951358 O.07511324 OCX http://www.streetinsider.com/Globe+Newswire/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html <ul><li><strong>Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits</strong></li><li><strong>Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients</strong></li><li><strong>Data was presented at the European Renal Association (ERA) 2025</strong></li><li><strong>Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2</strong></li><li><strong>Upcoming National Principal Investigator and Key Opinion Leader call planned</strong><br/></li></ul> <p>NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a http://www.streetinsider.com/Globe+Newswire/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html Mon, 23 Jun 2025 16:05:00 -0400 A.19718279 IMDX O.01951358 O.07511324 OCX http://www.streetinsider.com/Globe+Newswire/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html <ul><li><strong>Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits</strong></li><li><strong>Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients</strong></li><li><strong>Data was presented at the European Renal Association (ERA) 2025</strong></li><li><strong>Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2</strong></li><li><strong>Upcoming National Principal Investigator and Key Opinion Leader call planned</strong><br/></li></ul> <p>NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a http://www.streetinsider.com/Globe+Newswire/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html Mon, 23 Jun 2025 16:05:00 -0400 A.19718279 IMDX O.01951358 O.07511324 OCX http://www.streetinsider.com/Globe+Newswire/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html <ul><li><strong>Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits</strong></li><li><strong>Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients</strong></li><li><strong>Data was presented at the European Renal Association (ERA) 2025</strong></li><li><strong>Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2</strong></li><li><strong>Upcoming National Principal Investigator and Key Opinion Leader call planned</strong><br/></li></ul> <p>NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a http://www.streetinsider.com/Globe+Newswire/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html Mon, 23 Jun 2025 16:05:00 -0400 A.19718279 IMDX O.01951358 O.07511324 OCX http://www.streetinsider.com/Globe+Newswire/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html <ul><li><strong>Study indicates iMDx flagship technology’s equivalence with commercially available dd-cfDNA test kits</strong></li><li><strong>Head-to-head comparison of iMDx’s digital PCR-based test kits with NGS kits shows consistent results in 96 transplant patients</strong></li><li><strong>Data was presented at the European Renal Association (ERA) 2025</strong></li><li><strong>Extended data to be presented at the European Society of Organ Transplantation (ESOT) Congress in London, June 29 – July 2</strong></li><li><strong>Upcoming National Principal Investigator and Key Opinion Leader call planned</strong><br/></li></ul> <p>NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in a http://www.streetinsider.com/Globe+Newswire/iMDx+Reports+Strong+Head-to-Head+Data+in+Kidney+Transplant+Rejection+Testing/24965034.html Mon, 23 Jun 2025 16:05:00 -0400 A.19718279 IMDX O.01951358 O.07511324 OCX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Oncocyte+Corp+++++++++++++For%3A+Jun+13/24944297.html si-local-file:///var/storage/secattach/20250617/24944297.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Oncocyte+Corp+++++++++++++For%3A+Jun+13/24944297.html Tue, 17 Jun 2025 07:34:00 -0400 O.07511324 OCX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Oncocyte+Corp+++++++++++++For%3A+Jun+13/24944297.html si-local-file:///var/storage/secattach/20250617/24944297.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Oncocyte+Corp+++++++++++++For%3A+Jun+13/24944297.html Tue, 17 Jun 2025 07:34:00 -0400 O.07511324 OCX http://www.streetinsider.com/Press+Releases/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html <ul type="disc"><li style="margin-bottom:8pt;">New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care</li><li style="margin-bottom:8pt;">iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally</li><li style="margin-bottom:8pt;">Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025<br/><br/></li></ul> <p>NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company’s common stock, listed on the Nasdaq http://www.streetinsider.com/Press+Releases/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html Tue, 17 Jun 2025 07:00:00 -0400 A.36025252 IMDX O.07511324 O.21904527 OCX http://www.streetinsider.com/Press+Releases/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html <ul type="disc"><li style="margin-bottom:8pt;">New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care</li><li style="margin-bottom:8pt;">iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally</li><li style="margin-bottom:8pt;">Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025<br/><br/></li></ul> <p>NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company’s common stock, listed on the Nasdaq http://www.streetinsider.com/Press+Releases/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html Tue, 17 Jun 2025 07:00:00 -0400 A.36025252 IMDX O.07511324 O.21904527 OCX http://www.streetinsider.com/Press+Releases/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html <ul type="disc"><li style="margin-bottom:8pt;">New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care</li><li style="margin-bottom:8pt;">iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally</li><li style="margin-bottom:8pt;">Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025<br/><br/></li></ul> <p>NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company’s common stock, listed on the Nasdaq http://www.streetinsider.com/Press+Releases/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html Tue, 17 Jun 2025 07:00:00 -0400 A.36025252 IMDX O.07511324 O.21904527 OCX http://www.streetinsider.com/Press+Releases/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html <ul type="disc"><li style="margin-bottom:8pt;">New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care</li><li style="margin-bottom:8pt;">iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally</li><li style="margin-bottom:8pt;">Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025<br/><br/></li></ul> <p>NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company’s common stock, listed on the Nasdaq http://www.streetinsider.com/Press+Releases/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html Tue, 17 Jun 2025 07:00:00 -0400 A.36025252 IMDX O.07511324 O.21904527 OCX http://www.streetinsider.com/Press+Releases/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html <ul type="disc"><li style="margin-bottom:8pt;">New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care</li><li style="margin-bottom:8pt;">iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally</li><li style="margin-bottom:8pt;">Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025<br/><br/></li></ul> <p>NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company’s common stock, listed on the Nasdaq http://www.streetinsider.com/Press+Releases/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html Tue, 17 Jun 2025 07:00:00 -0400 A.36025252 IMDX O.07511324 O.21904527 OCX http://www.streetinsider.com/Globe+Newswire/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html <ul type="disc"><li style="margin-bottom:8pt;">New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care</li><li style="margin-bottom:8pt;">iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally</li><li style="margin-bottom:8pt;">Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025<br/><br/></li></ul> <p>NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company’s common stock, listed on the Nasdaq http://www.streetinsider.com/Globe+Newswire/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html Tue, 17 Jun 2025 07:00:00 -0400 A.36025252 IMDX O.07511324 O.21904527 OCX http://www.streetinsider.com/Globe+Newswire/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html <ul type="disc"><li style="margin-bottom:8pt;">New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care</li><li style="margin-bottom:8pt;">iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally</li><li style="margin-bottom:8pt;">Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025<br/><br/></li></ul> <p>NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company’s common stock, listed on the Nasdaq http://www.streetinsider.com/Globe+Newswire/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html Tue, 17 Jun 2025 07:00:00 -0400 A.36025252 IMDX O.07511324 O.21904527 OCX http://www.streetinsider.com/Globe+Newswire/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html <ul type="disc"><li style="margin-bottom:8pt;">New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care</li><li style="margin-bottom:8pt;">iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally</li><li style="margin-bottom:8pt;">Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025<br/><br/></li></ul> <p>NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company’s common stock, listed on the Nasdaq http://www.streetinsider.com/Globe+Newswire/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html Tue, 17 Jun 2025 07:00:00 -0400 A.36025252 IMDX O.07511324 O.21904527 OCX http://www.streetinsider.com/Globe+Newswire/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html <ul type="disc"><li style="margin-bottom:8pt;">New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care</li><li style="margin-bottom:8pt;">iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally</li><li style="margin-bottom:8pt;">Exhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025<br/><br/></li></ul> <p>NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (“iMDx” or the “Company”), (Nasdaq: IMDX), formerly known as Oncocyte Corporation (Nasdaq: OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company’s common stock, listed on the Nasdaq http://www.streetinsider.com/Globe+Newswire/Oncocyte+Changes+Name+to+Insight+Molecular+Diagnostics+Inc.+%28iMDx%29%2C+Moves+Headquarters+to+Nashville/24944096.html Tue, 17 Jun 2025 07:00:00 -0400 A.36025252 IMDX O.07511324 O.21904527 OCX